Aurora Cannabis (TSE:ACB) PT Set at C$10.00 by Canaccord Genuity Group

Aurora Cannabis (TSE:ACB) has been given a C$10.00 target price by Canaccord Genuity Group in a research note issued on Tuesday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 65.56% from the stock’s current price.

Separately, ATB Capital cut their price objective on shares of Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating on the stock in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of C$9.25.

Aurora Cannabis Stock Up 1.7%

Shares of ACB traded up C$0.10 during trading hours on Tuesday, hitting C$6.04. The stock had a trading volume of 237,421 shares, compared to its average volume of 475,242. The firm has a 50 day simple moving average of C$6.24 and a 200-day simple moving average of C$6.69. The firm has a market capitalization of C$339.73 million, a P/E ratio of -5.92 and a beta of 0.71. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48. Aurora Cannabis has a 1-year low of C$4.95 and a 1-year high of C$9.90.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Wednesday, November 5th. The company reported C($0.91) EPS for the quarter. Aurora Cannabis had a negative net margin of 22.55% and a negative return on equity of 8.36%. The firm had revenue of C$90.37 million for the quarter. Sell-side analysts predict that Aurora Cannabis will post -0.22 EPS for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.